| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
"IND Clearance" example | IND | — | Subscribe to access the data. | Small Molecules | Infectious Diseases | ||
"IND Clearance" example | IND | — | Subscribe to access the data. | Small Molecules | Infectious Diseases | ||
"IND Clearance" example | IND | — | Subscribe to access the data. | Small Molecules | Infectious Diseases |
Recent Updates
Recently added Catalysts
Traws Pharma, Inc.$0.76
+0.06 (+9.61%)
D 33Pipeline Score Overvalued Biotech · Commercial
Market Cap
22.57 M
EPS
-2.27
P/E Ratio
-
Value Trade
320.92 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
4.91 M
Operating CF
-2.58 M
Total Assets
8.16 M
Total Liabilities
13.47 M
Equity
-5.31 M
D/E Ratio
12,345
-3.87 %
Week
14.62 %
1 Month
-5.1 %
3 Month
-32.27 %
6 Month
-99.39 %
5 Year
-100 %
All Time
Cash Data
Cash Position
3.13 M
Monthly Burn
859.00 K
Runway
2 mo
Burn Trend
SEC Filing
May 15, 2026
Overview
Volume
124.71 K
52 Week Range
1.00 - 3.27
% held by Insiders
16.63 %
% held by Institutions
24.95 %
Enterprise Value
19.44 M
Total Shares
7.99 M
Short %
19.75 %
Float Shares
4.96 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Traws Pharma, Inc.
499Total events
3Upcoming
99Tier-1 (high impact)
2013 – 2027Coverage
Upcoming catalysts 3
Event history 496
Q3 2026
◆MHRA Milestonetivoxavir marboxilEx-US Regulatory
Updated toxicology data package resubmission to MHRA for TXM Phase 2a Challenge study
seasonal influenza prophylaxissource ↗
Jun 12, 2026
▼MHRA Milestonetivoxavir marboxilEx-US Regulatory
MHRA negative review of tivoxavir marboxil Phase 2a challenge study
influenzasource ↗
Jun 12, 2026
▼Trial Pausedtivoxavir marboxilTrial
Phase 2a human influenza challenge study deferred
influenzasource ↗
Jun 2026
●Trial Initiationtivoxavir marboxilTrial
Seasonal influenza virus prophylaxis Challenge Study at hVIVO
Seasonal Influenza (prophylaxis)source ↗
May 27, 2026
◆Preclinical PoCPreclinical
Advancing non-clinical development in validated animal models of Hantavirus and Ebola
Hantavirus, Ebola, Lassasource ↗
May 27, 2026
◆Manufacturing MilestoneCMC / Inspection
Scaling up chemical development and manufacturing infrastructure for immediate supply
Hantavirus, Ebola, Lassasource ↗
May 27, 2026
◆Other Regulator MilestoneEx-US Regulatory
Planned interactions with CDC, ongoing with NAFDAC and AMA to fast-track development
Hantavirus, Ebola, Lassasource ↗
May 8, 2026
◆Development Candidate NominationPreclinical
Plans to advance potential clinical candidates for hantavirus treatment
hantavirus infectionssource ↗
Apr 15, 2026
Drug Pipeline Intelligence
D33
Pipeline Score $5M
Pipeline ValueOvervalued
Valuation Signal5
Drugs Scored0.2x
rNPV / MCap Top 41%
Micro Cap (rank 538 of 911)
Percentile RankTraws Pharma, Inc. faces pipeline headwinds (33/100), with $1.1B risk-adjusted pipeline value, led by TRX-100 in Influenza (Phase 2), across $105B in total addressable markets, but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TRX-100 Small molecule | Influenza | Phase 2 | NCT07371650 | 21% | $416M | ACTIVE NOT_RECRUITING | 270 | SLOW | C (45) | Jan 1, 2027 | LOW_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
ratutrelvir | COVID-19 | Phase 2 | 2026-01-27 | 90-patient, open-label Phase 2 study; ratutrelvir 600 mg orally, once daily for 10 days; PAXLOVID® administered as nirmatrelvir 300 mg twice daily plus 100 mg ritonavir twice daily for 5 days Read More | Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza Read More | |
ratutrelvir | COVID-19 | Phase 2 | 2026-01-27 | 90-patient, open-label Phase 2 study; ratutrelvir 600 mg orally, once daily for 10 days; PAXLOVID® administered as nirmatrelvir 300 mg twice daily plus 100 mg ritonavir twice daily for 5 days Read More | Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza Read More | |
ratutrelvir | COVID-19 | Phase 2 | 2026-01-27 | 90-patient, open-label Phase 2 study; ratutrelvir 600 mg orally, once daily for 10 days; PAXLOVID® administered as nirmatrelvir 300 mg twice daily plus 100 mg ritonavir twice daily for 5 days Read More | Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in TRAW
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
TRAW Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
TRAWTraws Pharma Provides Updated Guidance on Influenza Prophylaxis Program
Traws Pharma has announced the development of an updated toxicology data package for tivoxavir marboxil (TXM) in response to the UK's MHRA requirements. This package is intended to support a Phase 2a influenza Challenge study in healthy volunteers, with resubmission expected in Q3 2026. TXM has demonstrated efficacy against various influenza strains, highlighting its potential as an oral prophylactic agent.
Read more →TRAW▼ -41%on this news
Traws Pharma Provides Regulatory Update on Influenza Program
Traws Pharma announced a deferral of its Phase 2a human influenza challenge study for tivoxavir marboxil due to negative feedback from the UK's MHRA. Despite this setback, the company emphasizes the potential of its antiviral candidates and maintains a commitment to developing long-acting influenza treatments. The program remains a priority, especially for vulnerable populations.
Read more →TRAWTraws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks Broad-spectrum antiviral agent with potential utility against Hantavirus, Ebola and Lassa Utilizing a novel dual-str
Traws Pharma has announced a new antiviral program aimed at addressing the ongoing outbreaks of Hantavirus and Ebola Virus Disease. The proprietary combination agent utilizes a dual-strike mechanism to effectively lower the necessary drug concentration for treatment. The company is collaborating with the CDC and the NAFDAC to expedite clinical development and prepare for swift manufacturing and distribution. This initiative reflects Traws Pharma's commitment to combatting critical global viral threats with innovative solutions.
Read more →TRAW▲ +15.3%on this news
Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results
Traws Pharma reported significant business highlights and financial results for Q1 2026, including a successful private financing of up to $60 million. The company is advancing its lead program, tivoxavir marboxil, towards a human influenza challenge trial and is also developing treatments for hantavirus infections. However, the FDA has placed a clinical hold on the U.S. IND for TXM due to toxicology concerns.
Read more →TRAW▲ +28.2%on this news
Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections
Traws Pharma is progressing with clinical candidates aimed at treating Hantavirus infections, a serious health threat with a high fatality rate. The company is leveraging its antiviral drug development expertise to address this urgent need, especially given the lack of approved treatments. Their strategy includes utilizing existing antiviral assets and proprietary chemical libraries to identify effective therapies.
Read more →TRAWTraws Pharma Reports Full Year 2025 Results and Provides Business Highlights
Traws Pharma reported its financial results for 2025, highlighting advancements in its investigational programs, including tivoxavir marboxil for influenza and ratutrelvir for COVID-19. The company secured $60 million in private financing, expected to support operations into Q1 2027. Positive Phase 2a data for ratutrelvir indicates a differentiated profile compared to existing treatments. However, the company is facing a clinical hold from the FDA on its TXM program.
Read more →TRAW▼ -22.6%on this newsshared move
Traws Pharma Announces Up to $60 Million Private Placement Financing
Traws Pharma has announced a successful private placement financing of up to $60 million, led by Sirenia Capital Management. The initial $10 million will support a human challenge trial for tivoxavir marboxil in the UK, with additional milestone-based proceeds potentially bringing the total to $60 million. The financing positions Traws to advance its influenza program while maintaining access to further capital.
Read more →TRAW▼ -20.3%on this news
Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID -Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for S
Traws Pharma has completed an analysis of its Phase 2 clinical study for ratutrelvir, demonstrating favorable outcomes against PAXLOVID for COVID-19 patients, including fewer adverse events and quicker symptom resolution. The company is also advancing its investigational compound, Tivoxavir Marboxil, which showed significant pre-clinical promise as a prophylactic treatment for seasonal influenza. However, the FDA has placed this compound's IND application on clinical hold due to concerns regarding mutagenicity. Traws Pharma is currently addressing these concerns to continue its clinical development plan.
Read more →TRAWTraws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
Traws Pharma has completed enrollment in a Phase 2 study of ratutrelvir, an oral COVID-19 treatment, which shows promise in patients unable to take PAXLOVID. The study indicates ratutrelvir has a favorable safety profile and may help reduce the risk of Long COVID. Additionally, Traws is advancing tivoxavir marboxil for influenza prophylaxis, with a challenge study planned for June 2026.
Read more →TRAW▲ +26.8%on this news· ran to +59% by day 3
Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients
Traws Pharma has filed a U.S. IND application for tivoxavir marboxil, a potential treatment for influenza, marking a key step for its inclusion in the national stockpile. The company also reported updated interim results for ratutrelvir, an investigational COVID-19 therapy, which demonstrated a favorable safety and efficacy profile compared to PAXLOVID. The study aims to address treatment gaps for patients ineligible for existing therapies.
Read more →TRAW▼ -36.4%on this news
Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients
Traws Pharma has reported positive interim clinical data for ratutrelvir, an investigational COVID-19 treatment, showing a favorable profile compared to PAXLOVID™. The drug demonstrated efficacy in patients who are ineligible for PAXLOVID™, with fewer adverse events and no viral rebounds observed. The final data analysis is expected in January 2026.
Read more →TRAW▼ -17.3%on this news
Traws Pharma Reports Third Quarter 2025 Results and Business Highlights
Traws Pharma reported its third-quarter results for 2025, highlighting progress in Phase 2 studies for ratutrelvir, an investigational treatment for COVID-19. The company acquired significant intellectual property and achieved cost reductions. However, it faced a net loss of $4.0 million and a drop in revenue to zero compared to the previous year.
Read more →TRAWTraws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025
Traws Pharma has commenced dosing in a Phase 2 study to evaluate ratutrelvir, a ritonavir-free antiviral treatment for COVID-19. This trial aims to compare its safety and efficacy against PAXLOVID, focusing on disease rebound and Long COVID. A separate trial will assess ratutrelvir in patients ineligible for PAXLOVID. Results from both studies are anticipated by the end of 2025.
Read more →TRAWTraws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives
Traws Pharma has appointed Dr. John Leaman as an independent director and confirmed the roles of Iain Dukes and Charles Parker as CEO and CFO, respectively. This move is aimed at strengthening the company's governance and leadership as it advances its lead antiviral candidate, ratutrelvir, for COVID-19. The company is focused on developing novel therapies targeting respiratory viral diseases.
Read more →TRAW▼ -6%on this news
Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025
Traws Pharma has received approval to initiate Phase 2 studies for ratutrelvir, a ritonavir-free COVID-19 treatment. The trials will compare ratutrelvir's efficacy against PAXLOVID and assess its safety in patients ineligible for PAXLOVID. Results are expected by the end of 2025, with potential implications for vulnerable populations and the broader COVID treatment market.
Read more →TRAWTraws Pharma Reports Second Quarter 2025 Results and Business Highlights Advancing novel programs for respiratory viruses that pose pandemic threats or risk of serious illness, including SARS CoV2 (ratutrelvir) and influ
Traws Pharma has reported its Q2 2025 financial results and highlighted advancements in its antiviral programs targeting respiratory viruses, including ratutrelvir for COVID-19 and influenzavirus. The company is preparing to initiate Phase 2 trials for ratutrelvir in newly diagnosed COVID patients, while also receiving regulatory approvals for its flu-related studies. Despite recent progress, Traws faces recruitment challenges for its bird flu study and reported a notable net loss for the quarter. The overall sentiment reflects optimism regarding their novel therapies amid a public health crisis.
Read more →TRAWTraws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025
Traws Pharma, Inc. will host a conference call on August 14, 2025, to discuss its second quarter financial results and recent business developments. The company focuses on developing antiviral therapies for respiratory viral diseases, including COVID-19 and seasonal influenza. Traws is also seeking partners for its oncology programs.
Read more →TRAWTraws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions
Traws Pharma has submitted multiple regulatory documents to advance its antiviral pipeline, including a Phase 2 study for tivoxavir marboxil (TXM) targeting seasonal and bird flu. Additionally, a Phase 2 study for ratutrelvir in newly diagnosed COVID patients has been proposed. The company is seeking accelerated approval for TXM through discussions with the FDA.
Read more →TRAWNASDAQ: TRAW June 2025 Corporate Presentation Forward - looking statements 2 This presentation contains, and certain oral statements made by management from time to time may contain, "forward - looking state ments" withi
Traws Pharma, Inc. outlined its corporate strategies in a June 2025 presentation, emphasizing their focus on forward-looking statements regarding product development and market potential. The company aims to advance several antiviral candidates, including a program for bird flu and a protease inhibitor targeting COVID-19. Despite optimism around these initiatives, multiple risks and uncertainties remain, including potential delays in clinical trials and challenges in securing necessary funding. The company’s progress will significantly hinge on its interactions with regulatory agencies and the success of ongoing clinical evaluations.
Read more →TRAW▲ +31.7%on this news
Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib
Traws Pharma announced the publication of promising efficacy data for rigosertib in treating RDEB-associated SCC. The study, published in the British Journal of Dermatology, reports an 80% overall response rate and 50% complete responses among evaluable patients. The company is actively seeking partners for further development of this therapy, which addresses a critical unmet need.
Read more →TRAW▲ +31.7%on this newsshared move
Traws Pharma - Rigosertib June 2025 Forward - looking statements This presentation contains, and certain oral statements made by management from time to time may contain, "forward - looking state ments" within the meanin
Traws Pharma provided an update regarding the diagnostic and clinical progression of Rigosertib, focusing on various ongoing and completed studies. The company highlighted its collaborations with notable academic institutions and clarified the complexities surrounding the development process of Rigosertib for clinical indications, particularly in recessive dystrophic epidermolysis bullosa and squamous cell carcinoma. However, the update also acknowledges significant uncertainties and risks pertaining to regulatory approvals, study timelines, and potential clinical results.
Read more →TRAW▲ +6.9%on this news
Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness
Traws Pharma has received FDA guidance on tivoxavir marboxil (TXM) for treating bird flu and seasonal flu. The company plans to pursue stockpiling of TXM for pandemic preparedness, supported by positive preclinical data. Traws Pharma is engaging with BARDA and international agencies to expedite development and approval processes.
Read more →TRAW▲ +6.9%on this newsshared move
NASDAQ: TRAW May 2025 Corporate Presentation Forward - looking statements 2 This presentation contains, and certain oral statements made by management from time to time may contain, "forward - looking state ments" within
Traws Pharma is focusing on developing antiviral therapies to target significant viral threats, including bird flu and COVID-19. The company has reported positive results from its ongoing Phase 1 trials and is engaged in discussions with regulatory agencies regarding its product candidates. However, Traws faces various risks associated with clinical development timelines, capital needs, and the realization of product values. The company continues to receive backing from notable investors as it seeks to navigate these challenges.
Read more →TRAW▲ +12.6%on this news
NASDAQ: TRAW May, 2025 Corporate Presentation Forward - looking statements 2 This presentation contains, and certain oral statements made by management from time to time may contain, "forward - looking state ments" withi
Traws Pharma, Inc. is actively developing first-in-class antiviral therapies targeting critical viral threats, including bird flu and COVID-19. The company has made progress in clinical development, particularly with its bird flu program and COVID therapy, showing promising Phase 1 safety data. However, Traws faces significant uncertainties related to regulatory approvals, clinical trial timelines, and the financial requirements necessary for advancement. Their 2024 merger with Trawsfynydd Therapeutics also presents potential challenges in fully realizing expected benefits.
Read more →TRAW▼ -11.3%on this newsshared move
Traws Pharma Reports First Quarter 2025 Results and Business Highlights
Traws Pharma has released its financial results for the first quarter of 2025, highlighting advancements in its antiviral programs for bird flu, seasonal flu, and COVID-19. The company is preparing to meet with regulatory authorities to discuss potential accelerated approvals for its lead candidates, tivoxavir marboxil and ratutrelvir. Positive preclinical data support the efficacy of these treatments, and Traws maintains a cash position adequate to fund operations through early 2026. Overall, Traws is poised for significant developments in the coming months.
Read more →TRAW▲ +5.5%on this news
Traws Pharma Reports First Quarter 2025 Results and Business Highlights FDA briefing document submitted
Traws Pharma, Inc. reported its financial results for the first quarter of 2025, revealing a strategic focus on advancing two investigational antiviral therapies for respiratory viral diseases: tivoxavir marboxil and ratutrelvir. The company is preparing to seek accelerated approval from regulatory authorities, supported by preclinical and initial study data. Traws highlighted a significant market opportunity in addressing viral threats and is actively engaging in discussions with the FDA regarding both therapies. The recent financial performance shows a net income driven by warrant liability changes, although overall cash reserves have decreased compared to previous quarters.
Read more →TRAWTraws Pharma Reports Full Year 2024 Results and Business Highlights Tivoxavir marboxil's potential as a single dose therapeutic agent for bird flu supported by significant antiviral activity in three well accepted animal
Traws Pharma has reported positive results for its lead candidate, tivoxavir marboxil, which shows potential as a single-dose therapeutic agent for bird flu, backed by strong antiviral activity in animal studies. The company is engaging with the FDA to explore accelerated approval under the Animal Rule. Financial results for the year ending December 31, 2024, included a significant net loss attributed primarily to research and financing expenses. Upcoming milestones include further regulatory discussions for bird flu treatment and continued development of COVID-19 therapies.
Read more →TRAW▼ -6.6%on this newsshared move
Traws Pharma Announces Management Updates Werner Cautreels, PhD, to retire as CEO, while continuing as a Board Member Iain D. Dukes, D Phil, Executive Board Chairman, to become Interim
Traws Pharma has announced significant management changes, with CEO Werner Cautreels retiring on March 31, 2025, transitioning to a special advisor role while continuing as a Board member. Iain D. Dukes will take over as Interim CEO, bringing extensive experience from leadership roles in other biopharmaceutical companies. The company's antiviral programs address critical health issues related to bird flu and COVID-19, continuing under Dukes' leadership. An Investor Update call is scheduled for March 31, 2025, to discuss the company's pipeline progress.
Read more →TRAW▼ -6.6%on this newsshared move
Traws Pharma Announces Management Updates
Traws Pharma, Inc. announced the retirement of its CEO, Werner Cautreels, effective March 31, 2025. Iain D. Dukes will take over as Interim CEO while maintaining his role as Executive Board Chairman. The company continues to develop antiviral therapies for bird flu and COVID-19, building on its recent merger and clinical progress. Dr. Cautreels will remain on the Board and serve as a special advisor for the next year.
Read more →TRAWTraws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET
Traws Pharma, Inc. has announced a virtual investor event scheduled for March 31, 2025, to discuss its product candidates Tivoxavir Marboxil for bird flu and Ratutrelvir for COVID-19. The event will include presentations from former CDC Director Robert R. Redfield, alongside Traws management. The company has provided positive preclinical and Phase 1 study data for both candidates and is preparing to engage with the FDA on next steps. Traws focuses on developing therapies that address critical health threats from respiratory viral diseases.
Read more →TRAW▼ -6.7%on this newsshared move
Traws Pharma's COVID-19 Candidate, Ratutrelvir, Presented at ICAR Preclinical and Phase 1 data suggest that ratutrelvir can be used without ritonavir and may reduce the likelihood of COVID rebound and the risk of long CO
Traws Pharma has presented promising preclinical and Phase 1 data for its COVID-19 treatment candidate, ratutrelvir, at the ICAR 2025 conference. The data suggest that ratutrelvir can be administered without the need for ritonavir, potentially simplifying treatment for patients and lowering associated drug interactions. Additionally, the candidate demonstrated high efficacy against various SARS-CoV-2 strains and favorable pharmacokinetics. The company is gearing up for discussions with the FDA and plans to initiate Phase 2 trials, with an investor event scheduled for March 31, 2025.
Read more →TRAWTraws Pharma Antiviral Bird Flu Program, Tivoxavir Marboxil, Shows Positive Data in Non-human Primates Tivoxavir marboxil (TXM), administered as a single dose in non-human primates, significantly reduced lung viremia and
Traws Pharma announced promising results for its antiviral candidate, tivoxavir marboxil (TXM), in a study involving non-human primates challenged with H5N1 bird flu. TXM significantly reduced lung viremia and prevented weight loss, marking key indicators of antiviral efficacy. Results build upon earlier studies in ferrets and mice that demonstrated increased survival and reduced viral load. The company plans to present further data at an upcoming investor event and is preparing FDA briefing documents for a potential accelerated approval path.
Read more →TRAWTraws Pharma's Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR Poster underscores Tivoxavir Marboxil's potential for the treatment of bird flu, supported by 100% survival in a rodent challenge model, poten
Traws Pharma presented findings on Tivoxavir Marboxil, an investigational treatment for bird flu, at the International Society for Antiviral Research. The data indicate a 100% survival rate in rodent models and suggest high safety and tolerability. Traws Pharma plans to discuss next regulatory steps with the FDA, aiming for an expedited approval process. The company also emphasizes TXM's potential effectiveness against seasonal influenza, expanding its market application.
Read more →TRAW▼ -30.8%on this news
Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil NEWTOWN, PA
Traws Pharma, Inc. announced promising results for its antiviral candidate, tivoxavir marboxil, in a ferret model for bird flu. The single-dose treatment demonstrated a reduction in viral burden and increased survival rates in infected ferrets. The company is preparing to conduct further studies in non-human primates, with results expected in early 2025, and aims to approach the FDA for accelerated approval under the Animal Rule. The developments come amid rising concerns over bird flu transmission to humans, underscoring the importance of effective antiviral solutions.
Read more →TRAWTraws Pharma Regains Compliance with NASDAQ Equity Listing Rule NEWTOWN, PA
Traws Pharma, Inc. has announced that it has regained compliance with Nasdaq's equity listing requirements, allowing it to continue trading under the symbol TRAW. This follows a significant financial boost from a $20 million offering aimed at strengthening the company's financial position. CEO Werner Cautreels highlighted the promising developments in Traws' antiviral pipeline, particularly targeting bird flu and influenza. However, the company will be under mandatory monitoring until February 2026 to ensure ongoing compliance.
Read more →TRAW▲ +12.2%on this news· ran to +29% by day 3
Traws Pharma Announces Completion of Phase I studies with Tivoxavir marboxil, a single dose oral investigational drug for the treatment and prevention of H5N1 Bird Flu Phase I completed in healthy volunteers with pharmac
Traws Pharma has announced the completion of Phase I clinical studies for Tivoxavir marboxil, a new oral drug aimed at treating and preventing H5N1 Bird Flu. The study involved healthy volunteers and demonstrated the drug’s safety and pharmacokinetic profile. Positive topline results indicated that Tivoxavir marboxil effectively inhibits the H5N1 virus, positioning it as a potential therapeutic option amidst the rising threat of bird flu. The company plans to use this data to guide future regulatory meetings and further drug development.
Read more →TRAW▲ +12.2%on this news· ran to +29% by day 3
Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu Traws Pharma, Inc. (NASDAQ: TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing oral small...
Traws Pharma has completed Phase I clinical studies for tivoxavir marboxil, an investigational drug aimed at treating and preventing H5N1 bird flu. The trial demonstrated safety and tolerability in healthy volunteers, supporting further development. The company emphasizes the urgent need for new antiviral therapies in light of recent bird flu threats.
Read more →TRAW▼ -37.3%on this news
Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to Approval Initial tranche of $20 Million extends ca
Traws Pharma, Inc. has announced a financing agreement to raise up to $72.6 million from notable institutional investors to advance the development of its drug Tivoxavir Marboxil for H5N1 bird flu. The initial tranche of $20 million will extend the company's cash runway into the first half of 2026. Traws highlighted the growing concern over bird flu infections and the potential for epidemic spread, making the development of their antiviral treatment increasingly crucial. The company plans to provide further updates on its clinical progress in 2025.
Read more →TRAW▼ -37.3%on this news
Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to Approval Traws Pharma, Inc. (NASDAQ: TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing oral small...
Traws Pharma, Inc. has secured financing of up to $72.6 million to advance the development of Tivoxavir Marboxil for treating H5N1 bird flu. The initial $20 million tranche will extend the company's cash runway into the first half of 2026, while the remaining funds depend on key data readouts in early 2025. The financing highlights investor confidence amid rising concerns over bird flu infections.
Read more →TRAW▲ +150.4%on this news· ran to +167% by day 3
Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu Traws Pharma, Inc. (NASDAQ: TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing oral small...
Traws Pharma has announced significant progress in developing tivoxavir marboxil for H5N1 bird flu. The Phase 1 trial has been completed successfully, showing safety and efficacy in healthy volunteers. The company plans to initiate a Phase 2 study in the first half of 2025, aiming to address the growing threat of avian influenza in humans.
Read more →TRAWTraws Pharma Provides Business Update and Reports Q3 2024 Financial Results COVID : Phase 1 pharmacokinetic profile supports the potential for ratutrelvir to be dosed as a once-a-day, single drug, 10-day treatment course
Traws Pharma announced a business update and reported its Q3 2024 financial results, highlighting progress in its clinical pipeline. The Phase 1 pharmacokinetic data for ratutrelvir suggests it could be a viable once-a-day monotherapy for COVID, demonstrating good tolerability and a lower risk of clinical rebound. Similarly, tivoxavir marboxil is supported as a potential one-time treatment for flu, including pandemic strains. However, the company also noted an increase in net loss and a substantial decrease in cash reserves over the past year.
Read more →TRAW▼ -8.4%on this news
Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil
Traws Pharma has announced positive topline Phase 1 results for its influenza treatment, tivoxavir marboxil, showing good tolerability and effective plasma levels. This investigational agent is being developed as a one-time treatment for seasonal and pandemic influenza, with promising preclinical data against drug-resistant strains. The company plans to initiate a Phase 2 study in the first half of 2025, enhancing hopes for an effective antiviral therapy. This development addresses a significant public health need given the burden of influenza, especially on vulnerable populations.
Read more →TRAWTraws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor
Traws Pharma, Inc. announced positive topline results for its COVID candidate, Ratutrelvir, an oral Mpro inhibitor, which demonstrated safety and consistent plasma levels in Phase 1 trials. The drug is designed to improve COVID treatment by eliminating the need for ritonavir, thus reducing drug-drug interaction risks. A Phase 2a study is anticipated to commence in the first half of 2025, addressing the ongoing demand for effective COVID therapies. With notable activity against resistant viruses, Ratutrelvir aims to provide a simplified treatment for high-risk patients.
Read more →TRAW▼ -8.3%on this news
Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors
Traws Pharma, Inc. announced the appointment of Luba Greenwood to its Board of Directors, bringing a wealth of experience in the life sciences sector. Greenwood's strategic expertise is expected to support Traws' development, particularly as the company advances its novel respiratory antiviral therapies and oncology strategy. Director James J. Marino will step down after nearly ten years with the company. The company is currently engaged in Phase 1 studies of its antiviral programs and is preparing for Phase 2 studies, reflecting its commitment to addressing unmet medical needs.
Read more →TRAWTraws Pharma, Inc. Announces Special Shareholders Meeting Results Three proposals, including a reverse stock split, were submitted and approved Traws Board subsequently approved a 1-for-25 reverse stock split Traws' shar
Traws Pharma, Inc. has announced the results of its 2024 Special Meeting of Shareholders, where all submitted proposals were approved. Notably, a reverse stock split of 1-for-25 was ratified, which is expected to take effect on September 20, 2024. As a result, Traws' common stock will begin trading on a split-adjusted basis on September 23, 2024. The company continues to focus on developing oral therapies for respiratory viral diseases and cancer.
Read more →TRAWTraws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights Merger with Trawsfynydd Therapeutics, Inc ("Trawsfynydd") and concurrent private placement of $14 million (cash runway to support planne
Traws Pharma, Inc. has reported its Q2 2024 financial results alongside notable business developments, including a merger with Trawsfynydd Therapeutics, Inc. This merger has helped to further diversify their portfolio and attract prominent healthcare investors. The company anticipates achieving crucial clinical milestones in their antiviral programs aimed at treating influenza and COVID-19. Despite reporting a significant net loss due to R&D costs, Traws has sufficient funds to maintain operations through the end of the year and is focusing on upcoming key readouts in 2025.
Read more →TRAW▼ -7.2%on this newsshared move
Traws Pharma to Host Corporate Update Call on August 15, 2024, at 8:00 AM ET
Traws Pharma, Inc. is set to hold a corporate update call on August 15, 2024, following the release of its second quarter financial results. The call will be accessible via a live webcast and dial-in options. Traws Pharma is focused on developing oral small molecule therapies for respiratory viral diseases and cancer, including advanced candidates currently in Phase 1 studies. The company's commitment to addressing unmet medical needs reflects its dedication to improving patient outcomes.
Read more →TRAWTraws Pharma’s ICAR Poster Highlights Potency of COVID-19 Candidate
Traws Pharma presented encouraging data on their COVID-19 candidate, ratutrelvir, at the ICAR2024 conference, showcasing its resistance profile against standard treatments. The preclinical studies indicate that ratutrelvir demonstrates superior efficacy compared to nirmatrelvir against various omicron variants. With the compound currently undergoing Phase 1 clinical trials, the company anticipates moving to Phase 2 studies in late 2024, potentially positioning ratutrelvir as a leading therapy for COVID-19.
Read more →TRAWTraws Pharma Reports First Quarter 2024 Financial Results and Provides Business Update Completed acquisition of Trawsfynydd and concurrent $14 million Capital Raise Excellent pipeline progress, led by candidates for COVI
Traws Pharma reported its financial results for Q1 2024, highlighting a transformative year with the successful acquisition of Trawsfynydd and a $14 million capital raise. The company showcased progress in its drug development pipeline, particularly with candidates for COVID-19 and influenza, and is set to initiate Phase 2 studies later in 2024. Despite a net loss of $5 million for the quarter, the company remains optimistic about its future clinical prospects and ongoing operations into the fourth quarter of 2024.
Read more →TRAWTraws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy
Traws Pharma has completed dosing of the first cohort in a Phase 1 clinical trial for travatrelvir, an investigational protease inhibitor aimed at treating COVID-19. The trial aims to evaluate the drug's safety, tolerability, and pharmacokinetics in healthy volunteers, with results expected in H2 2024. Travatrelvir has demonstrated activity against multiple SARS-CoV-2 variants in preclinical studies and does not require ritonavir co-administration, which could enhance its usability. The company is positioned to advance to further studies if the outcomes are favorable.
Read more →TRAWPotential best in class p roduct candidates in development for cancer & respiratory viral diseases April 2024 NASDAQ - TRAW Forward - looking statements This presentation contains, and certain oral statements made by man
Traws Pharma, Inc. is currently developing multiple product candidates aimed at treating cancer and respiratory viral diseases. The company announced that it has a cash balance of approximately $30.3 million and expects to initiate Phase 2 clinical trials for TRX01 and TRX100 later in 2024. Additionally, the development of narazaciclib, a multi-kinase inhibitor for refractory endometrial cancer, is ongoing. However, the company faces several risks related to regulatory approvals and potential delays in clinical development.
Read more →TRAWTraws Pharma Announces New Employee Inducement Grants
Traws Pharma, Inc. has announced the granting of equity awards to new employees following the acquisition of Trawsfynydd Therapeutics, Inc. by Onconova Therapeutics. The equity awards, amounting to various numbers of shares for different employees, were approved by the company's Compensation Committee. As Traws prepares for its NASDAQ debut, it continues to focus on developing innovative antiviral therapies. However, the company also faces several risks related to the merger and the development of its product candidates.
Read more →TRAWOnconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company - Closing cash balance of approximately $28 million ex
Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. have announced a merger to form a new company, Traws Pharma, Inc., which will focus on developing innovative treatments for viral infections and cancer. The merger is supported by a $28 million funding from OrbiMed and Torrey Pines, which is expected to facilitate the advancement of their promising product pipeline. Key assets include viroksavir for influenza and travaltrelvir for COVID-19, with critical clinical milestones set for 2024. The newly formed company will trade under the ticker 'TRAW' on NASDAQ beginning April 3, 2024.
Read more →TRAWOnconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results Narazaciclib progressing towards registrational studies; target engagement and acceptable safety profile support further d
Onconova Therapeutics provided a corporate update and announced its third quarter 2023 financial results, highlighting the progress of narazaciclib towards registrational studies for low-grade endometrioid endometrial cancer. The company is preparing for a conference call to discuss these results further. Notably, narazaciclib demonstrated an acceptable safety profile with low incidences of neutropenia and diarrhea compared to existing therapies. Additionally, Onconova plans to continue its development of rigosertib for a rare form of cancer.
Read more →TRAWOnconova Therapeutics Reports Corporate Update and Announces Second Quarter 2023 Financial Results Anticipate topline results from the Phase 1 monotherapy and Phase 1/2 combination study with letrozole in Q4 2023 Plans a
Onconova Therapeutics has reported its second quarter 2023 financial results alongside a corporate update, highlighting progress on its lead programs, narazaciclib and rigosertib. The company anticipates topline results from ongoing Phase 1 studies by Q4 2023 and is planning a registrational trial for rigosertib following a supportive FDA meeting. The recent appointment of Dr. Victor Moyo as Consulting Chief Medical Officer is expected to strengthen the leadership team. However, Onconova reported a net loss of $4.3 million for the quarter, reflecting ongoing financial challenges.
Read more →TRAWOnconova Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update Conference call and live webcast at 4:30 p.m. ET today NEWTOWN, PA.
Onconova Therapeutics reported its first quarter 2023 financial results and business update, highlighting key clinical developments and financial metrics. The company has commenced a Phase 1/2a trial of narazaciclib, aiming for a preliminary data readout later this year. Additionally, in their RDEB-associated squamous cell carcinoma program, Onconova expects positive regulatory discussions with the FDA following encouraging preliminary results. Financially, Onconova has maintained sufficient cash reserves to support its operations through early 2024, despite a reported increase in net loss compared to the previous year.
Read more →TRAWBy Electronic Delivery to: mguerin@onconova.us
Onconova Therapeutics, Inc. was notified by Nasdaq on March 28, 2023, regarding a failure to maintain a minimum bid price of $1.00 for its shares. However, the Company has since reported compliance, with its stock closing at or above the $1.00 mark for the last 10 consecutive business days. Consequently, the issue related to the Listing Rule 5550(a)(2) has been resolved, allowing the Company to continue its listing without further complications.
Read more →TRAWOnconova Therapeutics Announces the Unexpected Passing of Chief Medical Officer Dr. Mark Gelder NEWTOWN, PA
Onconova Therapeutics has announced the unexpected passing of its Chief Medical Officer, Dr. Mark Gelder. Dr. Gelder, who had served as CMO since June 2021, was known for his extensive experience in clinical development and his commitment to improving treatment for cancer patients. Michael Saunders, M.D., has been appointed as the interim CMO. Despite this tragic event, the company stated that it does not anticipate any material impact on its ongoing or planned clinical trials.
Read more →TRAWOnconova Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update Conference call and live webcast at 4:30 p.m. ET today NEWTOWN, PA.
Onconova Therapeutics reported its financial results for the full year of 2022, revealing a net loss of $19.0 million. The company received important IRB approval for its Phase 1/2a trial of narazaciclib, which is set to provide preliminary results later this year. Rigosertib also demonstrated efficacy in recent trials for certain cancer types, with plans for further investigator-sponsored trials. However, the company's cash reserves have notably decreased, and they expect to maintain operations only into the first quarter of 2024.
Read more →TRAWSent via Electronic Delivery to: mguerin@onconova.us
Onconova Therapeutics, Inc. was informed by Nasdaq on November 7, 2022, that its common stock had not maintained a minimum bid price of $1.00 for 30 consecutive business days. However, the company has since risen to compliance, achieving a closing bid price of $1.00 or greater for the last 10 consecutive business days, from January 30 to February 10, 2023. As a result, the company is now in compliance with Listing Rule 5550(a)(2), and the issue has been resolved.
Read more →TRAWOnconova Therapeutics Appoints Drs. Peter Atadja and Trafford Clarke to its Board of Directors NEWTOWN, PA.
Onconova Therapeutics Appoints Drs. Peter Atadja and Trafford Clarke to its Board of Directors NEWTOWN, PA., December 19, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), ("Onconova"), a clinical-stage biopharmaceutical company focused on discovering and d
Read more →TRAWOnconova Therapeutics Announces Plans for a Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer, Reports Third Quarter 2022 Financial Results, and Provides a Business Update Initiation of Phase
Onconova Therapeutics Announces Plans for a Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer, Reports Third Quarter 2022 Financial Results, and Provides a Business Update Initiation of Phase 1/2a endometrial cancer trial expected in 1Q23; prelimi
Read more →TRAWOnconova Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update Conference call and live webcast at 4:30 p.m. ET today NEWTOWN, PA.
Onconova Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update Conference call and live webcast at 4:30 p.m. NEWTOWN, PA., August 11, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), ("Onconova"), a clinical-stage biopharm
Read more →TRAWOnconova Therapeutics Announces Key Management Promotions Mark Guerin promoted to Chief Operating Officer and Chief Financial Officer Dr. Adar Makovski Silverstein promoted to Senior Director and Head of Corporate Develo
Onconova Therapeutics Announces Key Management Mark Guerin promoted to Chief Operating Officer and Chief Financial Officer Dr. Adar Makovski Silverstein promoted to Senior Director and Head of Corporate Development NEWTOWN, Pa., June 13, 2022 (GLOBE NEWSWIRE) - Onconova The
Read more →TRAWOnconova Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update Conference call and live webcast at 4:30 p.m. ET today NEWTOWN, PA.
Onconova Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update Conference call and live webcast at 4:30 p.m. NEWTOWN, PA., May 11, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), ("Onconova"), a clinical-stage biopharmaceu
Read more →TRAWOnconova Therapeutics Reports Full Year 2021 Financial Results and Provides Business Update Conference call and live webcast at 4:30 p.m. ET today NEWTOWN, PA.
Onconova Therapeutics Reports Full Year 2021 Financial Results and Provides Business Update and live webcast at 4:30 p.m. ET today March 17, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), ("Onconova"), a clinical-stage biopharmaceutical company focused
Read more →TRAWOnconova Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update Conference call and live webcast at 4:30 p.m. ET today NEWTOWN, PA.
Onconova Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update Conference call and live webcast at 4:30 p.m. NEWTOWN, PA., November 11, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), ("Onconova"), a clinical-stage biophar
Read more →TRAWOnconova Therapeutics, Inc. Announces Pricing of $21 Million Public Offering of Common Stock NEWTOWN, PA.
Onconova Therapeutics, Inc. Announces Pricing of $21 Million Public Offering of Common Stock NEWTOWN, PA., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) ("Onconova"), a biopharmaceutical company focused on discovering and developing novel produ
Read more →TRAWOnconova Therapeutics Announces Encouraging Clinical Data Supporting the Anti-Cancer Activity of Rigosertib-Nivolumab Combination in Advanced KRAS+ Non-Small Cell Lung Cancer Preliminary Phase 1/2a trial data show an ear
Onconova Therapeutics Announces Encouraging Clinical Data Supporting the Anti-Cancer Activity of Rigosertib-Nivolumab Combination in Advanced KRAS+ Non-Small 1/2a trial data show an early signal of activity in extensively pre-treated population with 2 partial responses out of 7
Read more →TRAWOnconova Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update Conference call and live webcast at 4:30 p.m. ET today NEWTOWN, Pa.
Onconova Therapeutics Reports Second Quarter Results and Provides Business Update Conference call and live webcast at 4:30 p.m. ET August 12, 2021 (GLOBE NEWSWIRE) - Onconova Therapeutics, Inc. (NASDAQ: ONTX) ("Onconova"), a clinical-stage biopharmaceutical company focused on
Read more →TRAWOnconova Therapeutics Regains Compliance with Nasdaq Continued Listing Requirement NEWTOWN, Pa.
Onconova Therapeutics Regains Compliance with Nasdaq Continued Listing Requirement June 22, 2021 (GLOBE NEWSWIRE) - Onconova Therapeutics, Inc. (NASDAQ: ONTX) ("Onconova"), a biopharmaceutical company focused on discovering and developing novel products for patients with cance
Read more →TRAWONCONOVA THERAPEUTICS
ONCONOVA THERAPEUTICS, INC. NOTICE TO HOLDERS OF TRADABLE WARRANTS You are hereby notified that, pursuant to Section 4.6 of the Warrant Agreement (the "Warrant Agreement"), dated as of July 27, 2016, by and between Onconova Therapeutics, Inc. (the "Company") and EQ Shareowner
Read more →TRAWOnconova Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update Conference call and live webcast at 4:30 p.m. ET today NEWTOWN, Pa.
Onconova Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update Conference call and live webcast at 4:30 p.m. ET May 17, 2021 (GLOBE NEWSWIRE) - Onconova Therapeutics, Inc. (NASDAQ: ONTX) ("Onconova"), a clinical-stage biopharmaceutical company
Read more →TRAWOnconova Therapeutics Reports Full Year 2020 Financial Results, Provides Business Update Conference call begins at 4:30 p.m. Eastern time today NEWTOWN, Pa.
Onconova Therapeutics Reports Full Year 2020 Financial Results, Provides Business Update Conference call begins at 4:30 p.m. Eastern NEWTOWN, Pa., March 11, 2021 (GLOBE NEWSWIRE) - Onconova Therapeutics, Inc. (NASDAQ: ONTX) ("Onconova"), a clinical-stage biopharmaceutical co
Read more →TRAWOnconova Therapeutics, Inc. Announces Closing of $28.75 Million Public Offering of Common Stock Including Full Exercise of the Over-Allotment Option NEWTOWN, PA.
Therapeutics, Inc. Announces Closing of $28.75 Million Public Offering of Common Stock Including Full Exercise of the Over-Allotment NEWTOWN, PA., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) ("Onconova"), a biopharmaceutical company focused on
Read more →TRAWOnconova Therapeutics, Inc. Announces Pricing of $25 Million Public Offering of Common Stock NEWTOWN, PA.
Therapeutics, Inc. Announces Pricing of $25 Million Public Offering of Common Stock PA., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) ("Onconova"), a biopharmaceutical company focused on discovering and developing novel products to treat cancer,
Read more →TRAWOnconova Therapeutics, Inc. Announces $8.7 Million Public Offering NEWTOWN, PA.
Onconova Therapeutics, Inc. Announces $8.7 Million Public Offering NEWTOWN, PA., January 7, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) ("Onconova"), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, toda
Read more →TRAWOnconova Therapeutics Announces FDA Permission for Study to Proceed Under its Investigational New Drug Application for Multi- kinase CDK4/6 Inhibitor ON 123300 Company affirms plans to begin enrollment of patients with H
Onconova Therapeutics Announces FDA Permission Proceed Under its Investigational New Drug Application for Multi- kinase CDK4/6 Inhibitor ON 123300 affirms plans to begin enrollment of patients with HR+ HER2- metastatic breast cancer and other tumors in U.S. Phase 1 trial in t
Read more →TRAWOnconova Therapeutics Files Investigational New Drug Application for Multi-kinase CDK4/6 Inhibitor ON 123300 U.S. Phase 1 trial patient enrollment to begin in the first half of 2021 China Phase 1 trial enrollment ongoing
Onconova Therapeutics Files Investigational New Drug Application for Multi-kinase CDK4/6 Inhibitor ON 123300 U.S. Phase 1 trial patient enrollment to begin in the first half of 2021 China Phase 1 trial enrollment ongoing Key regulatory milestone achieved to enable furthe
Read more →TRAWOnconova Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update ON 123300, our proprietary multi-kinase inhibitor, enters into the clinic for advanced solid tumors Investigator-initiated s
Onconova Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update Conference call begins at 4:30 p.m. ET NEWTOWN, Pa., November 12, 2020 (GLOBE NEWSWIRE) - Onconova Therapeutics, Inc. (NASDAQ: ONTX), a biopharmaceutical company focused on discove
Read more →TRAWOnconova Therapeutics Announces Topline Results from the Pivotal Phase 3 INSPIRE Trial IV rigosertib did not meet primary endpoint of significantly improved survival versus best supportive care in higher-risk myelodyspla
Onconova Therapeutics Announces Topline Results from the Pivotal Phase 3 INSPIRE Trial IV rigosertib did not meet primary endpoint of significantly improved survival versus best supportive care in higher-risk myelodysplastic syndromes (HR-MDS) Onconova will focus on promising
Read more →TRAWOnconova Therapeutics Highlights Corporate Progress and Reports Second Quarter 2020 Financial Results INSPIRE Phase 3 trial survival events reached Topline data anticipated Q3-2020 Conference call and webcast scheduled t
Onconova Therapeutics Highlights Corporate Progress and Reports Second Quarter 2020 Financial Results Conference call and webcast scheduled today, August 12, at 4:30 p.m. ET NEWTOWN, Pa., August 12, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase
Read more →TRAWOnconova Therapeutics Provides Corporate Update and Reports First Quarter 2020 Financial Results Conference Call and Webcast Scheduled Today, May 14 at 4:30 p.m.
Onconova Therapeutics Provides Corporate Update and Reports First Quarter 2020 Financial Results Conference Call and Webcast Scheduled Today, May 14 at 4:30 p.m. ET NEWTOWN, Pa., May 14, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage bio
Read more →TRAWOnconova Therapeutics Announces Completion of Enrollment of Phase 3 INSPIRE Trial, Provides a Corporate Update, and Reports 2019 Financial Results NEWTOWN, Pa.
Therapeutics Announces Completion of Enrollment of Phase 3 INSPIRE Trial, Provides a Corporate Update, and Reports 2019 Financial NEWTOWN, Pa., March 24, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on di
Read more →TRAWOnconova Therapeutics, Inc. Announces $10 Million Registered Direct Offering Priced At-The-Market NEWTOWN, PA.
Onconova Therapeutics, Inc. Announces $10 Million Registered Direct Offering Priced At-The-Market 31, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) ("Onconova" or the "Company"), a Phase 3-stage biopharmaceutical company discovering and developing novel p
Read more →TRAWOnconova Therapeutics, Inc. Announces Closing Of $5.0 Million Registered Direct Offering Priced At-The-Market NEWTOWN, Pa.
Onconova Therapeutics, Inc. Announces Closing Of $5.0 Million Registered Direct Offering Priced At-The-Market NEWTOWN, Pa., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) ("Onconova" or the "Company"), a Phase 3-stage biopharmaceutical company di
Read more →TRAWOnconova Therapeutics Announces Exclusive License Agreement with Specialised Therapeutics for Rigosertib in Australia and New Zealand Specialised Therapeutics receives exclusive license to commercialize rigosertib in Aus
Onconova Therapeutics Announces Exclusive License Agreement with Specialised Therapeutics for Rigosertib in Australia and New Zealand NEWTOWN, PA., Dec 18, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) ("Onconova"), a Phase 3-stage biopharmaceutical comp
Read more →TRAWOnconova Therapeutics Announces Data on Genomic Profiles of Higher Risk Myelodysplastic Syndromes Patients Refractory to Azacitidine Therapy Enrolled into the Pivotal INSPIRE Trial and Updated Oral Rigosertib Data Inform
Onconova Therapeutics Announces Data on Genomic Profiles of Higher Risk Myelodysplastic Syndromes Patients Refractory to Azacitidine Therapy Enrolled into the Pivotal INSPIRE Trial and Updated Oral Rigosertib Data Informing a Potential Adaptive Clinical Trial Design at the Amer
Read more →TRAWOnconova Therapeutics, Inc. Announces $5.0 Million Registered Direct Offering Priced At-the-Market NEWTOWN, PA.
Onconova Therapeutics, Inc. Announces $5.0 Million Registered Direct Offering Priced At-the-Market NEWTOWN, PA., Dec. 6, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) ("Onconova"), a Phase 3-stage biopharmaceutical company discovering and developing novel
Read more →TRAWInceptua Medicines Access and Onconova Therapeutics Announce Pre-approval Access Collaboration for Rigosertib in Selected Countries Outside the US NEWTOWN, PA., and LUXEMBOURG
Inceptua Medicines Access and Onconova Therapeutics Announce Pre-approval Access Collaboration for Rigosertib in Selected Countries Outside the US NEWTOWN, PA., and LUXEMBOURG, Dec 6, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) ("Onconova"), a Phase 3
Read more →TRAWOnconova Therapeutics, Inc. Announces $11.0 Million Public Offering NEWTOWN, PA.
Therapeutics, Inc. Announces $11.0 Million Public Offering NEWTOWN, PA., Nov 21, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) ("Onconova"), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with a focus
Read more →TRAWOnconova Affirms Planned Completion of Pivotal Phase 3 INSPIRE Study of Rigosertib in Myelodysplastic Syndromes by 1H20 And Provides Research & Development Update NEWTOWN, PA
Onconova Affirms Planned Completion of Pivotal Phase 3 INSPIRE Study of Rigosertib in Myelodysplastic Syndromes by 1H20 And Provides Research & Development Update NEWTOWN, PA, October 24, 2019 (GLOBE NEWSWIRE) Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmac
Read more →TRAWOnconova Therapeutics, Inc. Reports Business Highlights and Second Quarter 2019 Financial Results NEWTOWN, Pa.
Onconova Therapeutics, Inc. Reports Business Highlights and Second Quarter 2019 Financial Results NEWTOWN, Pa., August 14, 2019 Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company discovering and developing novel products to treat cancer, with
Read more →TRAWOnconova Therapeutics Announces License Agreement with HanX Biopharmaceuticals to Develop and Commercialize Rigosertib in Greater China Onconova to Receive $4 Million Upfront, including $2 Million Fee and $2 Million for
Onconova Therapeutics Announces License Agreement with HanX Biopharmaceuticals to Develop and Commercialize Rigosertib in Greater China Onconova to Receive $4 Million Upfront, including $2 Million Fee and $2 Million for Onconova Shares Purchased at a Premium, Plus up to $45.5
Read more →TRAWOnconova Therapeutics, Inc. Reports Business Highlights and First Quarter 2019 Financial Results NEWTOWN, Pa.
Onconova Therapeutics, Inc. Reports Business Highlights and First Quarter 2019 Financial Results NEWTOWN, Pa., May 14, 2019 Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug cand
Read more →TRAWOnconova Therapeutics, Inc. Reports Business Highlights and Full Year 2018 Financial Results NEWTOWN, Pa.
Onconova Therapeutics, Inc. Reports Business Highlights and Full Year 2018 Financial Results NEWTOWN, Pa., March 26, 2019 Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candid
Read more →TRAWOnconova Therapeutics Promotes Dr. Steven M. Fruchtman to Chief Executive Officer Executive succession plan maintains momentum of recent significant advances Onconova well-positioned to deliver key milestones in 2019 for
Onconova Therapeutics Promotes Dr. Steven M. Fruchtman to Chief Executive Officer Executive succession plan maintains momentum of recent significant advances Onconova well-positioned to deliver key milestones in 2019 for both intravenous and oral rigosertib, as well as other pi
Read more →TRAWOnconova Highlights Results from Phase 2 Trial of Oral Rigosertib In Combination with Azacitidine (Vidaza ) in Myelodysplastic Syndromes (MDS) at the 2018 ASH Annual Meeting Overall response rate (ORR) of 90% reported in
Onconova Highlights Results from Phase 2 Trial of Oral Rigosertib In Combination with Azacitidine (Vidaza ) in Myelodysplastic Syndromes (MDS) at the 2018 ASH Annual Meeting Overall response rate (ORR) of 90% reported in this multi-institutional Phase 2 study in hypomethylatin
Read more →TRAWOnconova Therapeutics Announces Business Highlights and Financial Results for Third Quarter 2018 Conference Call Today at 9:00 a.m. Eastern Time NEWTOWN, Pa.
Onconova Therapeutics Announces Business Highlights and Financial Results for Third Quarter 2018 Conference Call Today at 9:00 a.m. Eastern Time NEWTOWN, Pa., November 13, 2018 Onconova Therapeutics, Inc. (Nasdaq: ONTX), a Phase 3 stage biopharmaceutical company focused on deve
Read more →TRAWONCONOVA THERAPEUTICS, INC. NOTICE TO HOLDERS OF TRADABLE WARRANTS SEPTEMBER 25, 2018 You are hereby notified that, pursuant to Section 4.6 of the Warrant Agreement (the Warrant Agreement ), dated as of
ONCONOVA THERAPEUTICS, INC. NOTICE TO HOLDERS OF TRADABLE WARRANTS You are hereby notified that, pursuant to Section 4.6 of the Warrant Agreement (the Warrant Agreement ), dated as of July 27, 2016, by and between Onconova Therapeutics, Inc. (the Company ) and EQ Shareowner Ser
Read more →TRAWOnconova Therapeutics Reports Business Highlights and Financial Results for Second Quarter 2018 NEWTOWN, Pa.
Onconova Therapeutics Reports Business Highlights and Financial Results for Second Quarter 2018 NEWTOWN, Pa., August 14, 2018 Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on developing rigosertib, a novel small molecule drug candi
Read more →TRAWOnconova Therapeutics Announces Promotion for Steven M. Fruchtman, M.D. New Role as the President involves leadership of the entire product portfolio Promotion reflects progress of Rigosertib to key data milestones NEWTO
Onconova Therapeutics Announces Promotion for Steven M. Fruchtman, M.D. New Role as the President involves leadership of the entire product portfolio Promotion reflects progress of Rigosertib to key data milestones NEWTOWN, PA, June 21, 2018 (GLOBE NEWSWIRE) Onconova Therapeut
Read more →TRAWOnconova Therapeutics, Inc. Reports Business Highlights and Financial Results for First Quarter 2018 NEWTOWN, Pa.
Onconova Therapeutics, Inc. Reports Business Highlights and Financial Results for First Quarter 2018 NEWTOWN, Pa., May 15, 2018 Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug c
Read more →TRAWOnconova Therapeutics Announces Pricing of $25.0 Million Upsized Underwritten Public Offering NEWTOWN, PA
Onconova Therapeutics Announces Pricing of $25.0 Million Upsized Underwritten Public Offering NEWTOWN, PA, April 27, 2018 (Globe Newswire) Onconova Therapeutics, Inc. (NASDAQ:ONTX) ( Onconova or we ), a Phase 3 stage biopharmaceutical company focused on discovering and developin
Read more →TRAWOnconova Presents Data on Dual Inhibitor of CDK4/6 + ARK5 at American Association for Cancer Research 2018 Annual Meeting Onconova receives productive pre-IND guidance from FDA regarding first-in-class compound ON 123300
Onconova Presents Data on Dual Inhibitor of CDK4/6 + ARK5 at American Association for Cancer Research 2018 Annual Meeting Onconova receives productive pre-IND guidance from FDA regarding first-in-class compound ON 123300 Preclinical data reveals differential metabolism of ON 12
Read more →TRAWOnconova Therapeutics Announces License Agreement with Pint Pharma to Commercialize Rigosertib for Treatment of Myelodysplastic Syndromes in Latin America Pint Pharma to Make Upfront Investment in Onconova Onconova also
Onconova Therapeutics Announces License Agreement with Pint Pharma to Commercialize Rigosertib for Treatment of Myelodysplastic Syndromes in Latin America Pint Pharma to Make Upfront Investment in Onconova Onconova also Eligible to Receive up to $42.75 Million in Regulatory and
Read more →TRAWOnconova Therapeutics, Inc. Reports Business Highlights and Full Year 2017 Financial Results NEWTOWN, Pa.
Onconova Therapeutics, Inc. Reports Business Highlights and Full Year 2017 Financial Results NEWTOWN, Pa., March 8, 2018 (GLOBE NEWSWIRE) Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molec
Read more →TRAWOnconova Therapeutics Announces Pricing of $8.7 Million Underwritten Public Offering NEWTOWN, PA
Onconova Therapeutics Announces Pricing of $8.7 Million Underwritten Public Offering NEWTOWN, PA, February 8, 2018 (Globe Newswire) Onconova Therapeutics, Inc. (NASDAQ:ONTX) ( Onconova or we ), a Phase 3 stage biopharmaceutical company focused on discovering and developing small
Read more →TRAWCorporate Update
Corporate Update January 29, 2018 Nasdaq: ONTX This presentation contains forward-looking statements about Onconova Therapeutics, Inc. based on management s current expectations which are subject to known and unknown uncertainties and risks. Onconova has attempted to identify for
Read more →TRAWOnconova Moving Forward with Phase 3 INSPIRE Pivotal Trial with Increased Sample Size Following Promising Interim Analysis
Onconova Moving Forward with Phase 3 INSPIRE Pivotal Trial with Increased Sample Size Following Promising Interim Analysis Independent Data Monitoring Committee (DMC) recommends continuation of INSPIRE trial with trial expansion per adaptive design based on interim analysis resu
Read more →TRAWOnconova Therapeutics Announces Pricing of Public Offering of Common Stock
Onconova Therapeutics Announces Pricing of Public Offering of Common Stock NEWTOWN, PA., Nov. 10, 2017 (Globe Newswire) Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to tr
Read more →TRAWOnconova Therapeutics, Inc. Reports Business Highlights and Third Quarter 2017 Financial Results NEWTOWN, Pa.
Onconova Therapeutics, Inc. Reports Business Highlights and Third Quarter 2017 Financial Results NEWTOWN, Pa., November 9, 2017 (GLOBE NEWSWIRE) Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel smal
Read more →TRAWOnconova Therapeutics, Inc. Reports Recent Business Highlights and Second Quarter 2017 Financial Results NEWTOWN, Pa.
Onconova Therapeutics, Inc. Reports Recent Business Highlights and Second Quarter 2017 Financial Results NEWTOWN, Pa., August 15, 2017 (GLOBE NEWSWIRE) Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing nove
Read more →TRAWOnconova Therapeutics, Inc. Reports Recent Business Highlights and First Quarter 2017 Financial Results NEWTOWN, Pa.
Onconova Therapeutics, Inc. Reports Recent Business Highlights and First Quarter 2017 Financial Results NEWTOWN, Pa., May 15, 2017 (GLOBE NEWSWIRE) Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel sm
Read more →TRAWOnconova Therapeutics Announces Pricing of Public Offering of Common Stock Gross Proceeds to Support Phase 3 Trials of Rigosertib for Patients with Myelodysplastic Syndromes NEWTOWN, PA.
Onconova Therapeutics Announces Pricing of Public Offering of Common Stock Gross Proceeds to Support Phase 3 Trials of Rigosertib for Patients with Myelodysplastic Syndromes NEWTOWN, PA., April 21, 2017 (Globe Newswire) Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage
Read more →TRAWOnconova Therapeutics, Inc. Reports Recent Business Highlights and Year-end 2016 Financial Results NEWTOWN, PA
Onconova Therapeutics, Inc. Reports Recent Business Highlights and Year-end 2016 Financial Results NEWTOWN, PA, March 27, 2017 Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug ca
Read more →TRAWOnconova Presents Phase 2 Data from Oral Rigosertib and Azacitidine Combination Trial in Higher-Risk Myelodysplastic Syndromes (HR-MDS) at 2016 ASH Annual Meeting 35% Complete Remission (CR) Rate for Combination in 1 st
Onconova Presents Phase 2 Data from Oral Rigosertib and Azacitidine Combination Trial in Higher-Risk Myelodysplastic Syndromes (HR-MDS) at 2016 ASH Annual Meeting 35% Complete Remission (CR) Rate for Combination in 1st-line Higher-risk MDS Patients Updated Median Duration of Co
Read more →TRAWOnconova Therapeutics, Inc. Reports Recent Business Highlights and Third Quarter 2016 Financial Results NEWTOWN, PA
Onconova Therapeutics, Inc. Reports Recent Business Highlights and Third Quarter 2016 Financial Results NEWTOWN, PA, November 14, 2016 Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel produ
Read more →TRAWOnconova Announces Successful End-of-Phase 2 Meeting with FDA for Oral Rigosertib and Azacitidine Combination Pivotal Randomized Trial in 1 st -line MDS Patients will Assess Overall Response Rate as Approval Endpoint NEW
Onconova Announces Successful End-of-Phase 2 Meeting with FDA for Oral Rigosertib and Azacitidine Combination Pivotal Randomized Trial in 1st-line MDS Patients will Assess Overall Response Rate as Approval Endpoint NEWTOWN, PA, September 26, 2016 Onconova Therapeutics, Inc. (NA
Read more →TRAWOnconova Therapeutics, Inc. Reports Recent Business Highlights and Second Quarter 2016 Financial Results NEWTOWN, PA
Onconova Therapeutics, Inc. Reports Recent Business Highlights and Second Quarter 2016 Financial Results NEWTOWN, PA, August 15, 2016 Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel produc
Read more →TRAWOnconova Therapeutics, Inc. Reports Recent Business Highlights and First Quarter 2016 Financial Results NEWTOWN, PA
Onconova Therapeutics, Inc. Reports Recent Business Highlights and First Quarter 2016 Financial Results NEWTOWN, PA, May 11, 2016 Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products t
Read more →TRAWOnconova Therapeutics, Inc. Reports Recent Business Highlights and Year-end 2015 Financial Results Company Outlines Key Objectives for 2016 NEWTOWN, PA
Onconova Therapeutics, Inc. Reports Recent Business Highlights and Year-end 2015 Financial Results Company Outlines Key Objectives for 2016 NEWTOWN, PA, March 28, 2016 Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering
Read more →TRAWOnconova Therapeutics, Inc. Announces Listing Transfer to NASDAQ Capital Market NEWTOWN, PA
Onconova Therapeutics, Inc. Announces Listing Transfer to NASDAQ Capital Market NEWTOWN, PA, February 4, 2016 Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announ
Read more →TRAWOnconova Therapeutics Announces Registered Direct Offering Gross proceeds to support Phase 3 development of rigosertib in
Onconova Therapeutics Announces Registered Direct Offering Gross proceeds to support Phase 3 development of rigosertib in MDS NEWTOWN, PA, January 6, 2016 Onconova Therapeutics, Inc. (ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel
Read more →TRAWOnconova Presents Positive Data from Phase 2 Combination Trial of Oral Rigosertib and Azacitidine in Higher-Risk Myelodysplastic Syndromes at 2015 ASH Annual Meeting Combination Achieved 77 % Overall Response Rate in all
Onconova Presents Positive Data from Phase 2 Combination Trial of Oral Rigosertib and Azacitidine in Higher-Risk Myelodysplastic Syndromes at 2015 ASH Annual Meeting Combination Achieved 77% Overall Response Rate in all MDS Patients Overall Response Rate of 84% in treatment-na
Read more →TRAWOnconova Therapeutics, Inc. Reports Recent Business Highlights and Third Quarter 2015 Financial Results NEWTOWN, PA
Onconova Therapeutics, Inc. Reports Recent Business Highlights and Third Quarter 2015 Financial Results NEWTOWN, PA, November 11, 2015 Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to t
Read more →TRAWOnconova Announces Data Presentation from Phase 2 Combination Trial of Oral Rigosertib and Azacitidine at the 2015 ASH Annual Meeting MDS/AML Data Selected for Oral Presentation NEWTOWN, PA
Onconova Announces Data Presentation from Phase 2 Combination Trial of Oral Rigosertib and Azacitidine at the 2015 ASH Annual Meeting MDS/AML Data Selected for Oral Presentation NEWTOWN, PA, November 5, 2015 Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharma
Read more →TRAWOnconova Therapeutics Announces $16.5M Share Purchase Agreement with Lincoln Park Capital Fund NEWTOWN, PA
Onconova Therapeutics Announces $16.5M Share Purchase Agreement with Lincoln Park Capital Fund NEWTOWN, PA, October 8, 2015 Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer
Read more →TRAWOnconova Therapeutics, Inc. Reports Recent Business Highlights and Second Quarter 2015 Financial Results NEWTOWN, PA
Onconova Therapeutics, Inc. Reports Recent Business Highlights and Second Quarter 2015 Financial Results NEWTOWN, PA, August 13, 2015 Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to tr
Read more →TRAWOnconova Therapeutics, Inc. Reports Recent Business Highlights and First Quarter 2015 Financial Results NEWTOWN, PA
Onconova Therapeutics, Inc. Reports Recent Business Highlights and First Quarter 2015 Financial Results NEWTOWN, PA, May 14, 2015 Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat
Read more →TRAWOnconova Therapeutics, Inc. Reports Recent Business Highlights and Fourth Quarter and Year-End 2014 Financial Results Company Outlines Key Objectives for 2015 NEWTOWN, PA
Onconova Therapeutics, Inc. Reports Recent Business Highlights and Fourth Quarter and Year-End 2014 Financial Results Company Outlines Key Objectives for 2015 NEWTOWN, PA, March 26, 2015 Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focu
Read more →TRAWOnconova Announces Data Presentation from Combination of Rigosertib and Azacitidine in MDS and Non-proliferative AML at the 2014 ASH Annual Meeting Results from Phase 1 Trial of Oral Rigosertib and Azacitidine Combinatio
Onconova Announces Data Presentation from Combination of Rigosertib and Azacitidine in MDS and Non-proliferative AML at the 2014 ASH Annual Meeting Results from Phase 1 Trial of Oral Rigosertib and Azacitidine Combination Indicate Encouraging Rate of Response in MDS and AML NEW
Read more →TRAWOnconova Therapeutics, Inc. Reports Third Quarter 2014 Financial and Operational Results -Nine presentations to highlight programs including rigosertib Phase 3 trial at the ASH Annual Meeting- NEWTOWN, PA
Onconova Therapeutics, Inc. Reports Third Quarter 2014 Financial and Operational Results -Nine presentations to highlight programs including rigosertib Phase 3 trial at the ASH Annual Meeting- NEWTOWN, PA, November 13, 2014 Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical
Read more →TRAWOnconova Announces Ten Presentations at the 2014 ASH Annual Meeting Phase 3 ONTIME Trial Data Selected for Oral Presentation Data from Phase 1/2 Trial of Oral Rigosertib and Azacitidine Combination Highlighted NEWTOWN, P
Onconova Announces Ten Presentations at the 2014 ASH Annual Meeting Phase 3 ONTIME Trial Data Selected for Oral Presentation Data from Phase 1/2 Trial of Oral Rigosertib and Azacitidine Combination Highlighted NEWTOWN, PA, November 6, 2014 Onconova Therapeutics, Inc. (NASDAQ:
Read more →TRAWOnconova Therapeutics, Inc. Reports Second Quarter 2014 Financial and Operational Results NEWTOWN, PA
Onconova Therapeutics, Inc. Reports Second Quarter 2014 Financial and Operational Results NEWTOWN, PA, August 13, 2014 Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, tod
Read more →TRAWOnconova Therapeutics, Inc. Reports First Quarter 2014 Financial and Operational Results NEWTOWN, PA
Onconova Therapeutics, Inc. Reports First Quarter 2014 Financial and Operational NEWTOWN, PA, May 12, 2014 Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today provided
Read more →TRAWOnconova Therapeutics, Inc. Reports Fourth Quarter and Year-End 2013 Financial Results and Outlines Key Objectives for 2014 NEWTOWN, PA
Onconova Therapeutics, Inc. Reports Fourth Quarter and Year-End 2013 Financial Results and Outlines Key Objectives for 2014 NEWTOWN, PA, March 10, 2014 Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing no
Read more →TRAWth Annual Cowen Healthcare Conference
Treatment after failure of those first-line therapies are disappointing overall, with many patients eventually requiring long-term transfusions Treating Lower-risk MDS P. Fenaux, Blood, 121(21):4280-6; Epub 2013 Apr 10 0 10 20 30 40 50 60 70 80 01-10 01-41 01-45 01-34 01-02 01-37
Read more →TRAWAnalyst Day
Supportive Care: Summary of Quality of Life Findings Physical Functioning .0002 .0040 Fatigue .0010 .0001 Dyspnea .0014 .0002 Insomnia .035 .025 Social Functioning .041 .156 Overall QoL <.0001 <.0001 Aza-C vs. Supportive Care Crossover Subset [n=191] [n=38] QoL QoL Scale [p] [p]
Read more →TRAWOnconova Announces Results of Interim Analysis of Metastatic Pancreatic Cancer Study NEWTOWN, PA
Onconova Announces Results of Interim Analysis of Metastatic Pancreatic Cancer Study NEWTOWN, PA, December 17, 2013 Onconova Therapeutics, Inc. (NASDAQ: ONTX) a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today a
Read more →TRAWOnconova Announces Presentation of Positive Data from Clinical Trials of Rigosertib in Myelodysplastic Syndromes (MDS) at the 2013 ASH Annual Meeting NEWTOWN, PA
Onconova Announces Presentation of Positive Data from Clinical Trials of Rigosertib in Myelodysplastic Syndromes (MDS) at the 2013 ASH Annual Meeting NEWTOWN, PA, December 9, 2013 Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on d
Read more →TRAWOnconova Therapeutics, Inc. Reports Third Quarter 2013 Financial and Operational Results NEWTOWN, PA
Onconova Therapeutics, Inc. Reports Third Quarter 2013 Financial and Operational Results NEWTOWN, PA, November 12, 2013 Onconova Therapeutics, Inc. (NASDAQ: ONTX) a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, tod
Read more →TRAWOnconova Therapeutics, Inc. Reports Second Quarter 2013 Financial and Operational Results NEWTOWN, PA
Onconova Therapeutics, Inc. Reports Second Quarter 2013 Financial and Operational Results NEWTOWN, PA, September 6, 2013 Onconova Therapeutics, Inc. (NASDAQ: ONTX) a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, to
Read more →TRAWOnconova Appoints Dr. Jerome Groopman and Anne VanLent to Board of Directors NEWTOWN, PA
Onconova Appoints Dr. Jerome Groopman and Anne VanLent to Board of Directors NEWTOWN, PA, July 29, 2013 Onconova Therapeutics, Inc. (NASDAQ: ONTX) today announced the appointment of Dr. Jerome Groopman and Anne VanLent to the Board of Directors. I am pleased to welcome Dr. Groo
Read more →Competitive Position
How TRAW ranks across every disease it competes inCompetitive Position is a premium feature
See how TRAW ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial